The global bronchodilators market has been witnessing steady growth over the past few years owing to high prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators are drugs that help open up constricted airways and make breathing easier. Some common types of bronchodilators include beta2-agonists, muscarinic antagonists/anticholinergics, and xanthines. These drugs work by relaxing the muscles in the airways and increasing airflow to the lungs. The increasing geriatric population susceptible to respiratory conditions and growing pollution levels leading to higher cases of asthma attacks are fueling the sales of bronchodilators globally.

Key Takeaways

Key players operating in the global bronchodilators market are GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva.

The rising demand for respiratory drugs across major countries is a key factor driving the bronchodilators market. According to the World Health Organization (WHO), over 235 million people suffer from asthma worldwide with a high prevalence witnessed in developed nations and growing burden in developing countries. This has led to higher sales of bronchodilators for asthma treatment globally.

The Bronchodilators Market Growth is also witnessing expansion in emerging economies due to increasing healthcare investments by governments and developmental activities creating awareness regarding respiratory illnesses. Major players are focused on penetrating untapped markets to strengthen their geographical presence.

Market drivers

The increasing pollution levels are significantly contributing to the growth of the global bronchodilators market. The rising air pollution has led to sharp rise in cases of COPD and asthma over the past decade. According to some reports, over 90% of the world population resides in areas exceeding the WHO air quality guidelines. This high level of air toxins is boosting the demand for bronchodilators worldwide.